Novel monoclonal antibodies against Menangle virus nucleocapsid protein

Aurelija Zvirbliene1, Indre Kucinskaite-Kodze, Mindaugas Juozapaitis

  • 1Institute of Biotechnology, V. Graiciuno 8, 02241 Vilnius Lithuania. azvirb@ibt.lt

Archives of Virology
|November 10, 2009
PubMed

Insights

Three new monoclonal antibodies (MAbs) were developed to detect Menangle virus (MenV), a cause of pig reproductive disease. These MAbs show promise for accurate immunohistological diagnosis of MenV infections in pigs.

Area of Science:

  • Veterinary Virology
  • Immunology
  • Molecular Biology

Background:

  • Menangle virus (MenV), a Paramyxoviridae family member, causes significant reproductive issues in pigs.
  • Accurate diagnostic tools are crucial for controlling MenV outbreaks.
  • Existing diagnostic methods may lack specificity or sensitivity.

Purpose of the Study:

  • To develop specific monoclonal antibodies (MAbs) for Menangle virus detection.
  • To characterize the reactivity and epitope mapping of newly generated MAbs.
  • To evaluate the utility of MAbs in immunohistological diagnosis of MenV infection.

Main Methods:

  • Generation of MAbs by immunizing mice with recombinant MenV nucleocapsid (N) protein.
  • Epitope mapping using truncated MenV N proteins.
  • Immunohistochemical staining of pig brain tissue from a field case.

Main Results:

  • Three IgG1 MAbs were successfully generated against the MenV N protein.
  • Two MAbs recognized epitopes within amino acid residues 430-460, and one recognized 460-490.
  • All MAbs specifically detected MenV in infected piglet brain tissue.

Conclusions:

  • Novel MAbs offer specific detection of Menangle virus.
  • These MAbs are valuable tools for the immunohistological diagnosis of MenV infection in pigs.
  • Further application in diagnostic assays can aid in disease management.

Related Concept Videos

Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...